Relying on the fatalism of endemics while passively awaiting international humanitarian handouts constitutes a political and financial heresy. When the Vaccine Alliance’s models announce for 2029 the arrival of next-generation serums capable of saving 7 million lives and generating $135 billion in economic returns, they reiterate an unyielding truth: public health prevention is the most profitable macroeconomic investment imaginable. With an estimated need of tens of millions of annual doses, the challenge is not merely to extend a hand to receive vials, but to build a logistical and industrial infrastructure capable of absorbing the shock without faltering.

Believing that our states can do without rigorous foresight and exempt themselves from a sovereign acquisition strategy amounts to economic suicide. Between the proliferation of clinical trials conducted on African soil and the tight budgetary arbitrations among various vaccine candidates, public authority must break with day-to-day management. Every franc invested in the fight against this scourge must cease to be seen as a social burden and become the foundation of a measurable productive dividend.

Eradicating this health burden demands iron will and absolute constancy from administration in the sanctuarization of prevention programs. It is now a matter of imposing medical innovation at the heart of our development priorities. To durably escape crises, Cameroon and its African partners must transform public health into an unshakable pillar of their economic sovereignty—dignified, autonomous, and sovereign.


Receive the echo of economics in this new biweekly edition of your economic publication Alpha Eco 

Happy reading 


EWC, DP

Tags: santé publique prévention vaccins investissement économique souveraineté sanitaire Afrique logistique médicale innovation médicale financement santé santé économique